Evaluation of Efficacy & Safety of Rituximab With Mycophenolate Mofetil in

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

The purpose of the study is to evaluate the efficacy on lung function 6 months after one course of rituximab (2 infusions) and mycophénolate mofétil (MMF) treatment compared to one course of placebo and 6 months of MMF treatment in a broad range of patients with Interstitial Lung Diseases (ILD) non-responders to a first line immunosuppressive treatment.

See also
Status	Clinical Trial	Phase
Terminated	`NCT01618721` - Detection and Characterization of Pulmonary Disease by Transthoracic Doppler (TTD)	N/A
Completed	`NCT00815711` - Idiopathic Pulmonary Fibrosis Registry for Future Studies
Completed	`NCT01361139` - Diagnosis of Cardio-Pulmonary Pathology Using Transthoracic Parametric Doppler (TPD)	N/A

NCT number	NCT02990286
Study type	Interventional
Source	University Hospital, Tours
Contact
Status	Completed
Phase	Phase 3
Start date	January 20, 2017
Completion date	February 17, 2020

Evaluation of Efficacy and Safety of Rituximab With Mycophenolate Mofetil in Patients With Interstitial Lung Diseases — EvER-ILD

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms